Clinical Trials
Skin and Joint Treatments – These investigational drug trials aim to decrease active lupus disease symptoms such as joint inflammation and skin manifestation. During these trials, patients can maintain their background nonbiologic lupus medications.
- A Study to Evaluate Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (POETYK SLE-2).
- A Study to Evaluate the Efficacy and Safety of BIIB059 (Litifilimab) in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care (TOPAZ-1).
Biorepository/Lab Research – These studies collect information from biological samples to help researchers learn more about lupus and to help design other studies in the future.
- Lupus Nexus Landmark Study: A Prospective Registry and Biorepository
- Caricchio Biorepository- Bacterial Curli & Systemic Lupus Erythematosus
- Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (“APS ACTION”) International Clinical Database and Repository
Breakthrough Treatments – Recent innovations in immunotherapy have brought forth a type of treatment that programs a patient’s own immune cells to destroy lupus-causing cells. These personal cell therapies are the most promising areas of lupus treatment and can help patients who do not respond to current treatments.
- A Phase 1, Open-Label, Multicenter Study of KYV 101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Lupus Nephritis (KYV-101-001)